Single Ventricle Repair — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Single ventricle repair encompasses a staged palliative surgical strategy for congenital heart defects in which only one functional ventricular chamber is present, making a normal two-ventricle circulation impossible. Rather than correcting the anatomy — which is structurally not feasible — the staged approach progressively routes systemic venous blood directly to the lungs (bypassing the heart pump), allowing the single functioning ventricle to serve as the sole systemic pump.

The strategy consists of three stages performed in sequence during the first 2–4 years of life: Stage 1 (Norwood procedure, performed in the first week of life) stabilises the newborn by providing reliable pulmonary blood flow and establishing the single ventricle as the systemic pump; Stage 2 (bidirectional Glenn shunt, performed at 4–6 months) connects the superior vena cava directly to the pulmonary artery, reducing the volume load on the heart; and Stage 3 (Fontan completion, performed at 2–4 years) connects the inferior vena cava to the pulmonary artery, completing the separation of systemic and pulmonary circulations and achieving a stable palliated physiology.

Single ventricle palliation is performed at specialist paediatric cardiac centres with multidisciplinary teams including congenital cardiac surgeons, paediatric cardiologists, cardiac intensivists, and specialist nursing. It represents some of the most complex surgery performed in any subspecialty of medicine.

Single ventricle palliation is indicated for all forms of functionally univentricular congenital heart disease where a biventricular repair is not feasible. The most common diagnosis is hypoplastic left heart syndrome (HLHS) — in which the left ventricle, aorta, and mitral valve are severely underdeveloped — accounting for approximately 25% of all deaths from congenital heart disease in the first year of life if untreated. HLHS has an incidence of 2–3 per 10,000 live births.

Other diagnoses requiring single ventricle palliation include: tricuspid atresia (absent tricuspid valve with an underdeveloped right ventricle); double-inlet left ventricle (DILV, where both atrioventricular valves open into the left ventricle); unbalanced atrioventricular septal defect (where the common AV valve and ventricular mass are so asymmetric that biventricular repair cannot be achieved); and heterotaxy syndrome with complex univentricular anatomy. Prenatal diagnosis by fetal echocardiography in the second trimester allows planned delivery at a specialist cardiac centre and immediate postnatal stabilisation, significantly improving outcomes.

Stage 1 — Norwood Procedure (performed in the first week of life, weight 3–4 kg): Under cardiopulmonary bypass and deep hypothermic circulatory arrest (cooling to 15–18°C), the pulmonary artery and aorta are reconstructed into a single 'neoaorta' using homograft patch material, ensuring unobstructed systemic outflow from the right ventricle. Reliable pulmonary blood flow is established via either a modified Blalock-Taussig shunt (subclavian-to-pulmonary artery) or a right ventricle-to-pulmonary artery conduit (Sano modification). The patent ductus arteriosus (which the neonate depends upon for pulmonary blood flow) is ligated. The atrial septum is excised to allow unrestricted pulmonary venous return from the left atrium. This stage carries the highest operative mortality (5–15%) of the three stages.

Stage 2 — Bidirectional Glenn / Hemi-Fontan (4–6 months of age): The superior vena cava is divided and connected end-to-side to the right pulmonary artery (Glenn anastomosis), directing superior vena caval blood (approximately 50% of systemic venous return) directly into the lungs. The previous systemic-to-pulmonary shunt is ligated. This reduces the volume overload on the single ventricle and allows the pulmonary vascular resistance to fall further.

Stage 3 — Fontan Completion (2–4 years of age): A Fontan conduit (extracardiac or lateral tunnel) is constructed to direct inferior vena caval blood to the pulmonary artery, completing the total cavopulmonary connection. A small fenestration (opening) in the Fontan conduit may be created to provide a right-to-left pop-off valve, improving cardiac output at the cost of mild systemic desaturation.

Without surgical palliation, hypoplastic left heart syndrome and other functional single ventricle defects are uniformly fatal within the first weeks to months of life. The Norwood/Glenn/Fontan strategy has transformed HLHS from a universally lethal condition to one in which 10-year survival is approximately 70–80% at established specialist centres.

Post-Fontan, the majority of surviving children live functionally active lives: attending mainstream school, participating in moderate exercise, and achieving developmental milestones. Neurodevelopmental outcomes have improved significantly with advances in bypass techniques, neonatal cardiac care, and early developmental intervention. Quality of life studies in Fontan survivors show most rate their health-related quality of life as good to excellent.

Ongoing advances include catheter interventions (fenestration closure, collateral embolisation, stenting obstructed conduits), advanced rhythm therapies (ablation, pacemakers), and liver transplantation for end-stage hepatic disease. Heart transplantation is an option for Fontan failure, though with limited donor organ availability and competing demands. Mechanical circulatory support as a bridge to transplantation is an emerging strategy. Each decade has brought meaningful improvements in survival statistics, and current neonates have better prognoses than previous generations.

Inter-stage mortality between Stages 1 and 2 remains 5–15% at most centres, representing the most vulnerable period, most commonly from circulatory instability, systemic desaturation, or sudden cardiac death at home. Overall survival from birth to Fontan completion (approximately age 3) is 60–80% at experienced centres.

Fontan-associated complications accumulate with time and are collectively termed 'Fontan failure.' Protein-losing enteropathy (PLE) — abnormal protein loss through the gut due to elevated Fontan pressures — occurs in 5–10% and carries a 5-year mortality of 50% if untreated. Plastic bronchitis — abnormal lymphatic casts obstructing the airways — is rare but life-threatening. Atrial arrhythmias (flutter, fibrillation) affect 30–50% of Fontan patients by age 30 due to extensive atrial scarring and chronic haemodynamic stress.

Liver fibrosis and cirrhosis from chronically elevated hepatic venous pressures occur in virtually all Fontan patients and may progress to hepatocellular carcinoma. Renal dysfunction, coagulopathy, and exercise intolerance (VO2max 60–70% of normal) are universal long-term features.

Each stage of single ventricle palliation requires admission to the paediatric cardiac intensive care unit (PCICU) following surgery. After the Norwood procedure, PCICU admission lasts 2–4 weeks on average, with mechanical ventilation, inotropic support, and meticulous haemodynamic management. Discharge home is followed by close outpatient monitoring.

The interstage period between Stage 1 and Stage 2 (0–6 months) is the highest-risk period for mortality, with 5–15% of Norwood survivors dying at home from sudden cardiovascular collapse before the Glenn shunt. Dedicated interstage monitoring programmes — involving home pulse oximetry, weight tracking, and frequent nursing contacts — have reduced interstage mortality from 15% to 5% in centres that implement them rigorously.

After Stage 2 (Glenn shunt), hospital stay is typically 5–10 days; recovery is generally smoother than Stage 1. After Stage 3 (Fontan), hospital stay is 7–14 days. Prolonged pleural effusions (fluid leaking from the lymphatic system into the pleural space) are a characteristic Fontan complication, sometimes requiring drainage. Long-term management requires lifelong cardiology follow-up, anticoagulation (aspirin or warfarin), and surveillance for late Fontan complications.